Why is Amdocs stock cratering 40% today?

Amdocs stock plunged 39.4% in pre-open trading to reach $37.83 after the company disclosed a dramatically weaker-than-expected fiscal 2027 outlook tied to an escalating legal dispute with T-Mobile, its most significant customer. While fiscal Q4 2026 results were in line with expectations — non-GAAP EPS of $1.98 and revenue of $1.194 billion — the forward guidance was devastating: full-year FY2027 revenue is projected to decline between 14.3% and 17.9% as reported, while adjusted EPS is expected to fall between 26% and 30% year-over-year. Both parties have issued notices asserting material breaches of their agreements and are threatening termination or arbitration, casting deep uncertainty over a relationship that had previously been a cornerstone of Amdocs’s North American revenue.

Adding to the selling pressure, Oppenheimer moved swiftly this morning to downgrade Amdocs from Outperform to Perform, citing the anemic FY2027 outlook and the unresolved nature of the T-Mobile dispute. The firm significantly lowered its estimates, and at least three other analysts also revised earnings forecasts downward. The company’s 12-month backlog fell 16.5% year-on-year, further signaling a contraction in near-term revenue visibility. Amdocs also announced the $340 million acquisition of insurance technology firm EIS, which, while strategically positioned as a long-term growth driver, adds financing costs that weigh on the already-compressed FY2027 profitability outlook.

From a broader market perspective, the macro environment offered no cover for Amdocs’s collapse. The S&P 500 gained 0.5%, the Dow Jones rose 1.0%, and the NASDAQ added 0.4% on the day, as markets navigated U.S. midterm election results with relative calm. The sharp divergence between Amdocs and the broader indices underscores that today’s move is entirely company-specific, with no sector-wide or macro catalyst to explain the magnitude of the decline.

Taken together, the combination of a catastrophic guidance revision, a high-profile customer dispute with no clear resolution timeline, a fresh analyst downgrade, and a deteriorating backlog created a perfect storm that sent shares to levels well below their 52-week low of $49.74. The pre-market price of $37.83 reflects the market’s sharp reassessment of Amdocs’s near-term earnings power and the significant execution risk now embedded in its fiscal 2027 outlook.